/PLRX
PLRX Stock - Pliant Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$1.23+1.65%
+$0.02 (+1.65%) • Dec 19
62
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.13
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.68
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+103.3%upside
Target: $2.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PLRX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.22 – $1.24
TARGET (TP)$2.50
STOP LOSS$1.13
RISK/REWARD1:12.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.30
52W High$14.26
52W Low$1.10
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $1.58M | $9.69M | $7.57M | $41.82M |
| Gross Profit | N/A | $1.58M | $9.69M | $7.57M | $41.82M |
| Gross Margin | N/A | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-228,365,000 | $-184,145,000 | $-127,200,000 | $-97,535,000 | $-41,645,000 |
| Net Income | $-210,304,000 | $-161,336,000 | $-123,321,000 | $-97,263,000 | $-41,533,000 |
| Net Margin | N/A | -10211.1% | -1273.3% | -1284.5% | -99.3% |
| EPS | $-3.47 | $-2.75 | $-2.94 | $-2.71 | $-1.17 |
Company Overview
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
43%
Hold / Neutral
8
57%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
6 Bullish8 Neutral/Bearish
Price Targets
$27
Average Target
↑ 2113.9% Upside
Now
$4
Low
$27
Average
$48
High
Based on 13 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 10th 2025 | JP Morgan | Downgrade | Underweight | - |
| March 4th 2025 | Cantor Fitzgerald | Resumed | Neutral | - |
| March 4th 2025 | Needham | Downgrade | Hold | - |
| March 3rd 2025 | Stifel | Downgrade | Hold | - |
| March 3rd 2025 | Leerink Partners | Downgrade | Market Perform | - |
| February 10th 2025 | JP Morgan | Downgrade | Neutral | - |
| February 10th 2025 | Canaccord Genuity | Downgrade | Hold | $4← $43 |
| February 10th 2025 | Oppenheimer | Downgrade | Perform | - |
| February 10th 2025 | Citigroup | Downgrade | Neutral | $4← $40 |
| February 10th 2025 | Wells Fargo | Downgrade | Equal Weight | $4← $41 |
| February 10th 2025 | RBC Capital Mkts | Downgrade | Sector Perform | $4← $45 |
| February 10th 2025 | H.C. Wainwright | Downgrade | Neutral | - |
| September 9th 2024 | Leerink Partners | Resumed | Outperform | $33← $46 |
| December 8th 2023 | Wells Fargo | Initiation | Overweight | $41 |
| May 18th 2023 | Canaccord Genuity | Initiation | Buy | $48 |
Earnings History & Surprises
PLRXBeat Rate
44%
Last 18 quarters
Avg Surprise
+2.1%
EPS vs Estimate
Beats / Misses
8/8
2 met exactly
Latest EPS
$-0.43
Q4 2025
EPS Surprise History
Q1 24
+14.8%
$-0.69vs$-0.81
Q2 24
-2.6%
$-0.78vs$-0.76
Q3 24
-8.2%
$-0.92vs$-0.85
Q4 24
+4.0%
$-0.95vs$-0.99
Q1 25
+17.2%
$-0.82vs$-0.99
Q2 25
-17.9%
$-0.92vs$-0.78
Q3 25
-14.5%
$-0.71vs$-0.62
Q4 25
+18.9%
$-0.43vs$-0.53
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 2, 2026 | $-0.44 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.53 | $-0.43 | +18.9% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.62 | $-0.71 | -14.5% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-0.78 | $-0.92 | -17.9% | ✗ MISS |
Q1 2025 | Mar 3, 2025 | $-0.99 | $-0.82 | +17.2% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.99 | $-0.95 | +4.0% | ✓ BEAT |
Q3 2024 | Aug 7, 2024 | $-0.85 | $-0.92 | -8.2% | ✗ MISS |
Q2 2024 | May 6, 2024 | $-0.76 | $-0.78 | -2.6% | ✗ MISS |
Q1 2024 | Feb 27, 2024 | $-0.81 | $-0.69 | +14.8% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.78 | $-0.70 | +10.3% | ✓ BEAT |
Q3 2023 | Aug 9, 2023 | $-0.73 | $-0.70 | +4.1% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.66 | $-0.67 | -1.5% | ✗ MISS |
Q1 2023 | Mar 9, 2023 | $-0.70 | $-0.72 | -2.9% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $-0.74 | $-0.65 | +12.2% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $-0.82 | $-0.82 | 0.0% | = MET |
Q2 2022 | May 9, 2022 | $-0.77 | $-0.78 | -1.3% | ✗ MISS |
Q1 2022 | Feb 28, 2022 | $-0.76 | $-0.68 | +10.5% | ✓ BEAT |
Q4 2021 | Nov 9, 2021 | $-0.71 | $-0.75 | -5.6% | ✗ MISS |
Q3 2021 | Aug 9, 2021 | $-0.64 | $-0.64 | 0.0% | = MET |
Latest News
Pliant Therapeutics Data From Phase 1 Dose Escalation Clinical Study Of PLN-101095 In Combination With Pembrolizumab Shows Anti-Tumor Activity; All Participants Demonstrate Large Increases In Plasma Interferon Gamma
📈 PositiveBenzinga•Dec 4, 2025, 12:36 PM
RBC Capital Maintains Sector Perform on Pliant Therapeutics, Lowers Price Target to $2
📉 NegativeBenzinga•Nov 7, 2025, 07:19 PM
Pliant Therapeutics Q3 EPS $(0.43) Beats $(0.52) Estimate
📈 PositiveBenzinga•Nov 6, 2025, 09:43 PM
JP Morgan Downgrades Pliant Therapeutics to Underweight
📉 NegativeBenzinga•Oct 10, 2025, 11:36 AM•Also:
Pliant ends development of idiopathic pulmonary fibrosis asset bexotegrast
📉 NegativeSeeking Alpha•Jun 27, 2025, 08:32 PM
Frequently Asked Questions about PLRX
What is PLRX's current stock price?
Pliant Therapeutics, Inc. (PLRX) is currently trading at $1.23 per share. The stock has moved +1.65% today.
What is the analyst price target for PLRX?
The average analyst price target for PLRX is $2.50, based on 1 analyst.
What sector is Pliant Therapeutics, Inc. in?
Pliant Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is PLRX's market cap?
Pliant Therapeutics, Inc. has a market capitalization of $0.08 billion, making it a small-cap company.
Does PLRX pay dividends?
No, Pliant Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADVM
Adverum Biotechnologies, Inc.
$4.36
Mkt Cap: $0.1B
ARTV
Artiva Biotherapeutics, Inc.
$4.74
Mkt Cap: $0.1B
CLNN
Clene Inc.
$6.68
Mkt Cap: $0.1B
COYA
Coya Therapeutics, Inc.
$5.49
Mkt Cap: $0.1B
GUTS
Fractyl Health, Inc. Common Stock
$2.20
Mkt Cap: $0.2B
MGNX
MacroGenics, Inc.
$1.50
Mkt Cap: $0.1B
OVID
Ovid Therapeutics Inc.
$1.47
Mkt Cap: $0.1B
STRO
Sutro Biopharma, Inc.
$9.98
Mkt Cap: $0.1B
WHWK
Whitehawk Therapeutics Inc
$2.56
Mkt Cap: $0.1B
ZNTL
Zentalis Pharmaceuticals, Inc.
$1.40
Mkt Cap: $0.1B
Explore stocks similar to PLRX for comparison